• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

盐酸左布比卡因原位凝胶注射剂的制备及其在动物体内的药代动力学和药效学

仝新勇, 李立民

仝新勇, 李立民. 盐酸左布比卡因原位凝胶注射剂的制备及其在动物体内的药代动力学和药效学[J]. 中国药科大学学报, 2015, 46(2): 209-213. DOI: 10.11665/j.issn.1000-5048.20150212
引用本文: 仝新勇, 李立民. 盐酸左布比卡因原位凝胶注射剂的制备及其在动物体内的药代动力学和药效学[J]. 中国药科大学学报, 2015, 46(2): 209-213. DOI: 10.11665/j.issn.1000-5048.20150212
TONG Xinyong, LI Limin. Preparation of levobupivacaine hydrochloride sustained-release in-situ gel injection and its pharmacokinetic and pharmacodynamic studies in animals[J]. Journal of China Pharmaceutical University, 2015, 46(2): 209-213. DOI: 10.11665/j.issn.1000-5048.20150212
Citation: TONG Xinyong, LI Limin. Preparation of levobupivacaine hydrochloride sustained-release in-situ gel injection and its pharmacokinetic and pharmacodynamic studies in animals[J]. Journal of China Pharmaceutical University, 2015, 46(2): 209-213. DOI: 10.11665/j.issn.1000-5048.20150212

盐酸左布比卡因原位凝胶注射剂的制备及其在动物体内的药代动力学和药效学

Preparation of levobupivacaine hydrochloride sustained-release in-situ gel injection and its pharmacokinetic and pharmacodynamic studies in animals

  • 摘要: 采用磷脂为基质的新型原位凝胶作为盐酸左布比卡因缓释注射剂的载体。通过筛选磷脂类型、磷脂/乙醇比例、水分比例确定稳定载药的处方。制备的处方进行了初步表征,符合原位凝胶的特点。进行了比格犬药代动力学考察,上述处方的tmax滞后,t1/2延长,缓释特征明显。在豚鼠中进行了药效学评价,上述处方局部麻醉效果显著,相对于市售注射液,可维持长达48~72 h的局麻效果。该新型原位凝胶具备良好的开发潜力。
    Abstract: The purpose of this study was to develop a novel phospholipidas-based in-situ gel sustained-release formulation of levobupivacaine hydrochloride injection. Appropriate formulation was screened based on the factors such as phospholipid type, ratio of phospholipid to ethanol, ratio of water to phospholipid-ethanol mixture, which indicated typical in-situ gel profiles. Pharmacokinetic study using beagles showed that there were delayed tmax and prolonged t1/2 in levobupivacaine plasma-time profile after administration of the phospholipidas-based in-situ gel formulation if compared to commercially available conventional levobupivacaine hydrochloride injection. Pharmacodynamic studies conducted on guinea-pig demonstrated that it maintained 48-72 hr regional anesthesia, much longer than that of the anesthesia in the group receiving conventional injection. Hence, this novel in-situ gel intended for injection is worthy of development.
  • [1] Andrea C, Marta P. Bupivacaine, levobupivacaine and ropivacaine:are they clinically different[J]?Best Pract Res Clin Anaesthesiol,2005,19(2):247-268.
    [2] Bajwa SJ,Kaur J.Clinical profile of levobupivacaine in regional anesthesia:a systematic review[J].J Anaesthesiol Clin Pharmacol,2013,29(4):530-539.
    [3] Tong YC,Kaye AD,Urman RD.Liposomal bupivacaine and clinical outcomes[J].Best Pract Res Clin Anaesthesiol,2014,28(1):15-27.
    [4] McAlvin JB,Reznor G,Shankarappa SA,et al.Local toxicity from local anesthetic polymeric microparticles[J].Anesth Analg,2013,116(4):794-803.
    [5] Zeng HL,Shi Z,Fu XD.Progress in clinical application of the bupivacaine liposome injectable suspension Exparel[J].ChinJ New Drugs(中国新药杂志),2014,23(14):1654-1658.
    [6] Judy S,Michael R.Sustained-Release Injectable Products(可注射缓释制剂)[M].Beijing:Chemical Industry Press,2005:136-137,152.
    [7] Skolnik A,Gan TJ.New formulations of bupivacaine for the treatment of postoperative pain:liposomal bupivacaine and SABER-Bupivacaine[J].Expert Opin Pharmacother,2014,15(11):1535-1542.
    [8] Qi N, Tang X, Lin X, et al. Sterilization stability of vesicular phospholipid gels loaded with cytarabine for brain implant[J].Int J Pharm,2012,427(2):234-241.
    [9] Zhang RZ, Deng YJ, Sun WP. Research progressin vesicular phospholipid gel[J].Chin J Pharm(中国药剂学杂志),2008,6(4):214-218.
计量
  • 文章访问数:  1396
  • HTML全文浏览量:  1
  • PDF下载量:  2943
  • 被引次数: 0
出版历程
  • 刊出日期:  2015-04-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭